PARTIAL SECTION 8 & 15 ACCEPTED AND ACKNOWLEDGED
on 01 Apr 2021
Last Applicant/ Owned by
Paasheuvelweg 25
Amsterdam
NL
1105BP
Serial Number
85907857 filed on 18th Apr 2013
Registration Number
4710280 registered on 31st Mar 2015
Correspondent Address
Zachary A. Aria
Filing Basis
1. intent to use
Disclaimer
NO DATA
UNIQURE
Research, product development and consultancy in the field of biotechnology, biologics, pharmaceutics, medical science, chemistry and biochemistry Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver d Read More
Classification Information
Class [044]
Medical, Beauty & Agricultural Services
Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders,] inherited disorders, genetic disorders and single gene disorders
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [042]
Computer & Software Services & Scientific Services
Research, product development and consultancy in the field of biotechnology, biologics, pharmaceutics, medical science, chemistry and biochemistry
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Viral medicines, gene therapy medicines, nucleic acid delivery medicines, viral vectors, [non-viral vectors,] gene therapy vectors, nucleic acid delivery vectors, [and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors] for medical purposes all for medical treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers;] pharmaceutical preparations and substances for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers;] biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy [and cell therapy,] all for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,]inherited disorders, genetic disorders, single gene disorders [and cancers;] [clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing in the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; pharmaceutical preparations, vaccines, prophylaxis medicines and other] pharmaceutical preparations [all] for use in nucleic acid-based therapy, gene therapy [and cell therapy] in the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers]
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [001]
Chemical Products
[Viral assays, viral reagents, viral preparations, gene therapy assays, gene therapy reagents, gene therapy preparations, nucleic acid delivery assays, nucleic acid delivery reagents, nucleic acid delivery preparations, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors, all for non-medical research purposes]
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 85907857
Mark Type
No Service Mark
Attorney Docket Number
No 140998-00101
44D Filed
No
44D Current
No
44E filed
Yes
44E Current
Yes
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 04th Oct 2024 | TEAS SECTION 8 & 9 RECEIVED |
| 31st Mar 2024 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED |
| 01st Apr 2021 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED |
| 01st Apr 2021 | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. |
| 10th Nov 2020 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| 17th Sep 2020 | TEAS SECTION 8 & 15 RECEIVED |
| 31st Mar 2020 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| 31st Mar 2015 | REGISTERED-PRINCIPAL REGISTER |
| 18th Nov 2014 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 18th Nov 2014 | 1(B) BASIS DELETED; PROCEED TO REGISTRATION |